Provided by Tiger Fintech (Singapore) Pte. Ltd.

Creative Medical Technology Holdings, Inc.

6.40
+0.41006.84%
Volume:151.03K
Turnover:969.87K
Market Cap:11.19M
PE:-1.68
High:6.75
Open:6.29
Low:5.80
Close:5.99
Loading ...

BUZZ-Creative Medical Technology rises on positive data for stem cell therapy

Reuters
·
14 Feb

Creative Medical Technology Holdings Announces Mid-Term Follow-up Study Data Reporting Significant Reduction in Opioid Use by Chronic Lower Back Pain Patients Undergoing Stemspine® Procedure Using Allostem™

THOMSON REUTERS
·
14 Feb

Creative Medical Technology Holdings Announces Mid-Term Follow-up Study Data Reporting Significant Reduction in Opioid Use by Chronic Lower Back Pain Patients Undergoing StemSpine® Procedure using AlloStem™

GlobeNewswire
·
14 Feb

Creative Medical Technology reports one-year results for AlloStem program

TIPRANKS
·
11 Feb

Creative Medical Technology Holdings Inc - Announces Promising One-Year Data From Allostem Type 2 Diabetes Study

THOMSON REUTERS
·
11 Feb

Creative Medical Technology Holdings Inc - Celz-201 Achieves 80% Efficacy in Reducing Insulin Dependency

THOMSON REUTERS
·
11 Feb

Creative Medical Technology Reports Positive One-Year Results for AlloStem™ Type 2 Diabetes Program

GlobeNewswire
·
11 Feb

Creative Medical Technology expands collaboration with Greenstone Biosciences

TIPRANKS
·
05 Feb

Creative Medical Technology Holdings Expands Collaboration With Greenstone Biosciences to Accelerate Ipscelz Pipeline Development

THOMSON REUTERS
·
05 Feb

Creative Medical Technology Holdings Expands Collaboration with Greenstone Biosciences to Accelerate iPSCelz Pipeline Development

GlobeNewswire
·
05 Feb

Creative Medical reports data from first cohort in Phase 1/2 CELZ-201-DDT trial

TIPRANKS
·
30 Jan

Creative Medical Technology Holdings Announces Positive Initial Safety, Tolerability, and Efficacy Data From First Cohort in Phase 1/2 Trial of Celz-201-Ddt for Chronic Back Pain

THOMSON REUTERS
·
30 Jan

Creative Medical Technology Holdings Announces Positive Initial Safety, Tolerability, and Efficacy Data from First Cohort in Phase 1/2 Trial of CELZ-201-DDT for Chronic Back Pain

GlobeNewswire
·
30 Jan

Creative Medical Gets Safety Approval in FDA-Cleared Back Pain Treatment Trial

MT Newswires Live
·
14 Nov 2024

Creative Medical advances FDA cleared ADAPT trial with independent review

TIPRANKS
·
13 Nov 2024

BRIEF-Creative Medical Technology Holdings, Inc. Advances FDA Cleared Adapt Clinical Trial With Positive Independent Review, Validating The Safety And Potential Of CELZ-201 For Chronic Lower Back Pain Treatment

Reuters
·
13 Nov 2024